The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

Wed, 14th Apr 2021 12:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Quixant PLC - Cambridge-based technology outsourcer for gaming industry - Revenue for 2020 falls 31% to USD63.8 million from USD92.3 million the year before due to Covid-19 "weighing heavily" on demand in the gaming business, and the firm swings to a pretax loss of GBP2.0 million from a profit of GBP9.4 million in 2019. Despite loss, Quixant declares dividend of 2.0 pence share, versus none in 2019. "The board is confident in the future prospects of the group which is reflected in our decision to recommend payment of a dividend," Chief Executive Jon Jayal says, adding that 2021 has started strongly with healthy order intake.

----------

Merchants Trust PLC - invests mainly in higher-yielding large UK companies - Net asset value per share ends financial year on January 31 at 458.5p compared to 551.5p at the same point a year before. During the recent year, NAV total return, with debt at market value, fell by 12%, compared with a 7.5% decrease for its benchmark, the FTSE All-Share index, on a total return basis. "Approximately half of the difference is accounted for by the gearing of the portfolio, which exacerbates market movements, in either direction. The board believes that over the long term, a prudent level of gearing should add value and enhance income for shareholders," company explains, adding: "Whilst the near 5% underperformance for the 2021 financial year is disappointing, it should be viewed in the context of an extremely strong 2020 financial year where the NAV total return was 8% above the benchmark, and also in terms of the strong recovery in the second half of 2020."

----------

Destiny Pharma PLC - Brighton, England-based biotechnology firm - Reports pretax loss of GBP6.5 million for 2020, widening from GBP5.5 million the year before. Company says it remains "financially robust" and well positioned to advance the development of its lead assets and earlier pipeline during 2021, with an estimated cash runway to the fourth quarter of 2022. "The strong balance sheet will provide Destiny Pharma with working capital through to Q4 2022 enabling it to complete the preparation of NTCD-M3 for its single Phase 3 study," the firm says.

----------

Anglo Pacific Group PLC - London-based natural resources royalty and streaming - Sinks to pretax loss of GBP27.2 million in 2020 from GBP37.6 million profit in 2019. Royalty revenue falls to GBP34.0 million from GBP55.7 million, as royalty income declines to GBP25.0 million from GBP45.1 million. "Results reflect lower production levels from Kestrel compared to the record level produced in 2019. 2020 volumes were 11% lower at 5.8 million tonnes which are expected to be the level the operators are targeting in the near-term," company explains. Annual dividend kept unchanged at 9 pence. Notes Vanessa Dennett will retire as a non-executive director. Search process now underway to replace Dennett.

----------

Futura Medical PLC - Surrey-based pharmaceutical company - Pretax loss in 2020 narrows to GBP2.9 million from GBP11.1 million in 2019. Research & development costs fall to GBP1.9 million from GBP10.1 million, and administrative costs slip to GBP1.0 million from GBP1.1 million. Reports no revenue in 2020 after GBP31,779 in 2019. Chair John Clarke says: "This year, against the backdrop of the turbulence and challenges posed by the Covid-19 pandemic, the team at Futura has been resolutely focused on gaining regulatory approval for MED3000 in Europe and the US. We look forward to receiving the EU certificate to enable MED3000 to be marketed as a breakthrough, fast acting, clinically proven OTC treatment for ED shortly as well as commencing the remaining clinical work we believe will also deliver a similar approval for MED3000 in the USA."

----------

Europa Oil & Gas Holdings PLC - UK, Ireland and Morocco focused oil and gas company - Reports revenue for half-year to January 31 of GBP516,000, down from GBP778,000 year-on-year. However, pretax loss narrows to GBP687,000 from GBP3.5 million a year ago, thanks to a GBP3.0 million exploration write-off in the prior-year period which did not repeat in the latest half. "The commencement of oil flow at Wressle, the extension to the Initial Phase of the Inezgane permit and the GBP1.44 million fundraise (net of fees) post period end, provide a strong foundation upon which to build on in the second half of the year," company says.

----------

Kooth PLC - London-based digital mental health platform - Pretax loss in 2020 widens to GBP1.9 million from GBP1.3 million loss in 2019. Annual revenue, however, improves to GBP13.0 million from GBP8.7 million. Annual recurring revenue rose 33% as company notes revenue ahead of expectations, driven by fee uplifts from existing clients and new business in Adult and CYP units. Administrative expenses grow to GBP10.0 million from GBP5.7 million. Says new year starts well with strong new business performance giving an ARR at March 31 of GBP15.9 million.

----------

By Paul McGowan; paulmcgowan@alliancenews.com and Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.